1887

n Southern African Journal of HIV Medicine - Stavudine dosage reduction : effect on symptomatic hyperlactataemia and lactic acidosis in patients at Dr George Mukhari Hospital, Pretoria : scientific letter

USD

 

Abstract

A range of studies have demonstrated that symptomatic hyperlactataemia and lactic acidosis are associated with antiretroviral combinations containing stavudine. The HIV treatment programme in Khayelitsha, Cape Town, which began using stavudine as a first-line therapy in 2003, reported approximately 10% of patients switching from stavudine to the alternative drug after 12 months due to hyperlactataemia. Following a meta-analysis showing that lower doses of stavudine are safer and as effective, the World Health Organization (WHO) issued a statement that only a low dose of stavudine (30 mg) should be used.

Loading

Article metrics loading...

/content/m_sajhiv/14/1/EJC132904
2013-03-01
2016-12-09
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error